Drug Delivery System Market Size Report & Global Outlook 2027

[Research Report] The drug delivery system market was valued at US$ 1,243,111.7 million in 2018 and it is projected to reach US$ 2,302,227.2 million in 2027; it is expected to grow at a CAGR of 7.2% from 2019 to 2027.

  

Analyst Perspective:

The global drug delivery system market is significantly driven by the rising prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer, coupled with technological advancements in the manufacturing and development of innovative devices for pharmaceutical drug delivery. Diabetes is a prominent reason behind kidney failure, heart attacks, blindness, and stroke. Therefore, the rapidly growing prevalence of various chronic diseases across the globe is significantly boosting the demand for various innovative drugs for treatment, which augments the drug delivery system market growth.

The rapidly growing biopharmaceutical industry and the development of various new and innovative drugs are significantly driving the growth of the drug delivery system market. The growing investments by the top pharmaceutical manufacturers in the research and development of new drugs to treat incurable diseases are augmenting the need for various pharmaceutical drug delivery solutions around the globe. Furthermore, several top market players in the drug delivery system market and the key developmental strategies such as product launches, mergers & acquisitions, and partnerships they adopted significantly drive the market growth. Therefore, the rising penetration of drug and gene delivery device companies across the globe is boosting the market growth.

Market Overview:

A drug delivery system (DDS) is a formulation or a device that enables the introduction of a therapeutic substance into the body that improves its efficacy and safety by controlling the rate, time, and place of release of drugs into the body. Drug delivery systems have substantially evolved over the last six decades. In the last 12 years majorly, there have been huge advancements in drug delivery technology. For instance, advanced medication delivery systems, such as transdermal patches, are able to deliver a drug more selectively to a specific site, which frequently leads to easier, more accurate, and less dosing overall. There are other drug delivery systems used in both medical and home care settings that were developed because of various patient needs, and researchers continue to develop new methods.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Drug Delivery Systems Market: Strategic Insights

Drug Delivery Systems Market

• 
  CAGR (2018 - 2027)

  7.2%
• Market Size 2018
  US$ 1,243.11 Billion
• Market Size 2027
  US$ 2,302.23 Billion

Market Dynamics

GROWTH DRIVERS

• XXXXXXX
• XXXXXXX
• XXXXXXX

FUTURE TRENDS

• XXXXXXX
• XXXXXXX
• XXXXXXX

OPPORTUNITIES

• XXXXXXX
• XXXXXXX
• XXXXXXX

Key Players

• BD Becton Dickinson Company
• Boston Scientific Corporation
• Novo Nordisk A S
• Bausch Health Companies Inc
• Baxter International Inc
• Boehringer Ingelheim
• Novartis AG
• GlaxoSmithKline plc
• Johnson Johnson Services Inc

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Route of Administration

• Oral
• Transmucosal
• Injectable
• Topical
• Implantable
• Ocular

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Application

• Hospitals & Clinics
• Home Care Settings
• Others

Geography

• North America
• Europe
• Asia Pacific
• Middle East and Africa
• South and Central America

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Market Driver:

Rising Incidence of Chronic Diseases to Drive Drug Delivery System Market Growth

As drug delivery devices help deliver the drugs, which are beneficial for the targeted population to recover faster, there has been a growing adoption of and inclination toward advanced drug delivery devices. Moreover, a rising number of cancers, respiratory disease, and diabetic patients worldwide may promote the adoption of drug delivery system and drive the overall market. According to the World Health Organization (WHO), cancer is the biggest cause of death worldwide, with approximately 10 million deaths in 2020. Overall, the global burden of cancer incidence and death is quickly increasing. As per the CDC, in 2020, 1,603,844 new cancer cases were reported, and 602,347 people died of cancer in the US. Breast, colorectal, lung, cervical, and thyroid cancers are common among women. In contrast, lung and prostate cancer is the most common among men, accounting for nearly one-third of all male cancers. This growing burden of cancer increases the adoption of drug delivery devices, contributing significantly to the drug delivery system market's growth.

Segmental Analysis:

Based on application, the drug delivery system market is categorized into homecare settings, hospitals & clinics and others. In 2018, hospitals and clinics segment held the major share in the drug delivery system market. The homecare settings segment is expected to register a significant growth in the drug delivery system market during the forecast period. The hospital is a complex organization and an institute that provides health to people through complicated but specialized scientific equipment and team of trained staff educated in the problems of modern medical science. They are all coordinated together for the common goal of restoring and maintain good health. Hospitals serves a significant role by providing extensive range of medical services to the patient population suffering from wide variety of diseases. This increased the adoption of drug delivery systems in hospitals and clinics. For instance, according to Centers for Disease Control and Prevention (CDC), in 2014, a total number of 7.2 million hospital discharges were reported with diabetes in the US among adult population aged 18 years or older. This is expected to increase the treatment process for controlling and treating chronic conditions, which in turn is expected to increase the usage of drug delivery systems in the hospitals.

Regional Analysis:

In North America, US is the largest market for drug delivery system market. The growth of this market is primarily driven by increasing prevalence of chronic diseases like diabetes, asthma and others, growing number of product launches by key players; and increasing use of drug delivery devices for disease management. According to the National Center for Health Statistics, in 2023, 1.9 million new cancer cases and 609,820 cancer deaths are projected to occur in the US, and cancer cases are further expected to increase in the country, which is expected to increase the demand for the drug delivery systems for various therapeutics as demand for cancer treatment is quite high in the region owing to the high mortality rate associated with the disease, which is expected to boost growth in the drug delivery system market.

The launch of new products in the country will also help drive drug delivery system market growth. For instance, in February 2022, the US FDA approved the generic Apokyn (apomorphine hydrochloride injection) drug cartridges to treat hypomobility and other episodes associated with advanced Parkinson’s disease. In January 2021, Novartis AG invested in Credence MedSystems to support the development and scale-up of its drug delivery systems. This initiative facilitates Novartis AG's use of Credence technology in its injectable medicines. Similarly, in November 2020, Croda International PLC entered into an agreement with Pfizer Inc. to supply innovative drug delivery systems for Pfizer’s COVID-19 vaccine candidate.

Furthermore, in March 2022, Corium received US FDA approval for Adlarity to treat patients with mild, moderate, or severe dementia associated with Alzheimer’s. The launch of transdermal patches in the country is expected to boost the studied market during the study period. Moreover, strategic initiatives by market players, such as partnerships and collaborations for increasing the production of drug delivery devices, would lead to lucrative market growth. For instance, in May 2020, the Department of Defense and the United States Department of Health and Human Services awarded a contract worth USD 138 million to ApiJect Systems America for "Project Jumpstart" and "RAPID USA," which will work together to expand the United States' production capability of medical-grade injection devices.

Key Player Analysis:

The drug delivery system market analysis consists of players, such as BD, 3M, Novo Nordisk A/S, BD, Novo Nordisk A/S, 3M, Boston Scientific Corporation, Bausch Health Companies Inc., Baxter International, Inc., Boehringer Ingelheim, Novartis AG, GlaxoSmithKline plc. and Johnson & Johnson Services, Inc. Among the players in the drug delivery system market, 3M and BD are the top two players owing to the diversified product portfolio offered.

Drug Delivery System Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Recent Developments:

 

Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the drug delivery system market. A few recent key market developments are listed below: 

• In June 2022, Gufic Biosciences Ltd launched a new drug delivery system, Dual Chamber Bags, at affordable prices for the first time in India. One of the most important USPs of these ready-to-use Dual Chamber Bags by Gufic is that they prevent contamination and protects the potency and efficacy of the drug. These bags also offer ease of handling at the time of reconstitution and also help in avoiding the dilution errors since the drug is present with the exact required quantity of the diluent to be used.
• In February 2022, Takeda received US FDA approval for TAKHZYRO (lanadelumab-flyo) injection in a single-dose prefilled syringe (PFS), which is used to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older. The PFS is ready to use and requires fewer preparation steps than the current TAKHZYRO vial injection, while also reducing supplies and waste.